Neuroinflammation in Alzheimer's Disease describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
Neuroinflammation is a central pathological feature of Alzheimer's disease (AD), characterized by chronic activation of glial cells (microglia and astrocytes) and elevated levels of pro-inflammatory mediators in the brain. While initially a protective response, sustained neuroinflammation becomes detrimental and contributes to neurodegeneration.
Microglia are the resident immune cells of the brain, derived from yolk sac progenitors. In AD, they undergo dramatic phenotypic changes:
Molecular Triggers:
- Amyloid-beta binds to TLRs (TLR2, TLR4), CD36, RAGE
- Tau oligomers activate TLRs and trigger inflammatory responses
- ** DAM (Disease-Associated Microglia) phenotype**
- TREM2 variants increase AD risk 2-4x
Astrocytes adopt a reactive phenotype in AD:
- Upregulation of GFAP
- Release of inflammatory mediators
- Impaired glutamate uptake
- Disrupted blood-brain barrier
flowchart TD
A["Aβ Deposition] --> B["Microglial Activation]
B --> C["Pattern Recognition<br/>Receptors"]
C --> D["TLR2/4<br/>CD36, RAGE<br/>TREM2"]
D --> E["NLRP3<br/>Inflammasome]
E --> F["Pro-IL-1β<br/>Pro-IL-18"]
F --> G["IL-1β, IL-18<br/>Release]
B --> H["NADPH Oxidase<br/>Activation"]
H --> I["ROS Production"]
I --> J["Oxidative Stress"]
J --> K["Neuronal Damage"]
G --> L["Cytokine Storm]
L --> M["IL-6<br/>TNF-α, IL-1β"]
M --> N["Synaptic<br/>Dysfunction]
N --> O["Axonal<br/>Degeneration"]
O --> P["Neuronal Death"]
Q["Astrocyte<br/>Activation] --> R["Complement<br/>System]
R --> S["C1q, C3b<br/>Opsonization"]
S --> T["Synaptic<br/>Pruning"]
T --> N
M --> U["Tau<br/>Phosphorylation"]
U --> V["NFT Formation"]
click A "/proteins/amyloid-beta" "Amyloid Beta"
click B "/cell-types/microglia" "Microglia"
click D "/mechanisms/trem2-signaling" "TREM2 Signaling"
click E "/mechanisms/nlrp3-inflammasome" "NLRP3 Inflammasome"
click L "/mechanisms/cytokine-storm-neuroinflammation" "Cytokine Storm"
click R "/mechanisms/complement-system-neurodegeneration" "Complement System"
click N "/mechanisms/synaptic-loss-ad" "Synaptic Loss"
style A fill:#e1f5fe,stroke:#333
style B fill:#ffcdd2,stroke:#333
style E fill:#ffcdd2,stroke:#333
style L fill:#ffcdd2,stroke:#333
style P fill:#ffcdd2,stroke:#333
style N fill:#ffcdd2,stroke:#333
style V fill:#ffcdd2,stroke:#333
style C fill:#fff3e0,stroke:#333
style D fill:#fff3e0,stroke:#333
style F fill:#fff3e0,stroke:#333
style G fill:#fff3e0,stroke:#333
style H fill:#fff3e0,stroke:#333
style I fill:#fff3e0,stroke:#333
style J fill:#fff3e0,stroke:#333
style K fill:#fff3e0,stroke:#333
style M fill:#fff3e0,stroke:#333
style O fill:#fff3e0,stroke:#333
style Q fill:#e1f5fe,stroke:#333
style R fill:#fff3e0,stroke:#333
style S fill:#fff3e0,stroke:#333
style T fill:#fff3e0,stroke:#333
style U fill:#fff3e0,stroke:#333
| Cytokine |
Source |
Effect in AD |
Reference |
| IL-1β |
Microglia |
Promotes tau pathology, synaptic dysfunction |
|
| IL-6 |
Astrocytes, Microglia |
Acute phase response, cognitive decline |
|
| TNF-α |
Microglia, Astrocytes |
Synaptic pruning, excitotoxicity |
|
| IL-18 |
Microglia |
IFN-γ induction, neurotoxicity |
|
- CCL2 (MCP-1) - recruits microglia to plaques
- CXCL12/SDF-1 - altered in AD brain
- CX3CL1 (Fractalkine) - neuroprotective, reduced in AD
The complement cascade is highly activated in AD:
- C1q - initiates complement, tags synapses for pruning
- C3 - opsonization, microglial activation
- C3a/C5a - anaphylatoxins, neuroinflammation
A specialized microglial phenotype characterized by:
- Stage 1: Homeostatic → early DAM (Trem2-independent)
- Stage 2: Late DAM (Trem2-dependent)
- Upregulation of lipid metabolism genes
- Increased phagocytic activity
¶ TREM2 and AD Risk
TREM2 variants are major AD risk factors:
- R47H - ~3x increased risk
- R62H - intermediate risk
- H157Y - risk variant
TREM2 functions:
- Aβ phagocytosis
- Microglial survival
- Lipid metabolism
- Inflammatory response modulation
| Gene |
Variant |
Effect |
Reference |
| TREM2 |
R47H |
~3x AD risk |
|
| CD33 |
rs3865444 |
Alters microglial activation |
|
| ABI3 |
rs616338 |
Increased risk |
|
| PLCG2 |
rs72849905 |
Protective |
|
| INPP5D |
Various |
Alters microglial signaling |
|
¶ Neuroinflammation and Other Pathologies
- Aβ activates microglia → inflammation → more Aβ production
- Chronic inflammation impairs Aβ clearance
- Inflammatory cytokines increase APP expression
¶ Tau and Inflammation
- IL-1β activates GSK-3β → tau phosphorylation
- Inflammation accelerates tau spreading
- Tau aggregates activate microglia
- C1q tags synapses for complement-mediated pruning
- TNF-α reduces synaptic function
- IL-1β impairs LTP
- IL-6 - elevated in AD
- YKL-40 (chitinase) - microglial activation
- sTREM2 - soluble TREM2, disease stage-dependent
- TSPO PET - measures microglial activation
- 11C-PK11195 - first-generation ligand
- 18F-GE-180 - second-generation
| Approach |
Target |
Status |
Reference |
| TREM2 agonists |
TREM2 |
Preclinical |
|
| NLRP3 inhibitors |
Inflammasome |
In trials |
|
| Anti-inflammatory drugs |
COX-2, NSAIDs |
Failed |
|
| Anti-cytokine therapy |
IL-1β, TNF-α |
In trials |
|
| Microglial modulation |
CSF1R inhibitors |
In trials |
|
Epidemiological studies suggested reduced AD risk with NSAIDs, but large RCTs failed to show benefit:
-可能是治疗时机太晚
Neuroinflammation connects to all AD pathological features:
- Amyloid cascade - bidirectional
- Tau pathology - accelerates spreading
- Mitochondrial dysfunction - ROS and energy
- Synaptic loss - complement-mediated pruning
- Alzheimer's Disease — Primary neurodegenerative disease
- Parkinson's Disease — Related neurodegenerative disease
- Amyloid Cascade Pathway - Key AD mechanism
- Tau Pathology - Tau-mediated neurodegeneration
The blood-brain barrier (BBB) plays a critical role in neuroinflammation in AD. BBB dysfunction allows peripheral immune cells and molecules to enter the brain .
BBB changes in AD include:
- Endothelial dysfunction: Reduced tight junction proteins
- Pericyte loss: Compromised barrier integrity
- Astrocyte end-feet damage: Impaired neurovascular coupling
- Transcytosis increase: Enhanced nanoparticle permeation
BBB breakdown enables peripheral immune cell entry:
- T lymphocytes: CD4+ and CD8+ T cells found in AD brain
- Monocytes: Contribute to microglial pool
- B cells: Rare but present in some cases
- NK cells: May have cytotoxic effects
Amyloid affects cerebral vasculature:
- Cerebral amyloid angiopathy (CAA): Aβ in vessel walls
- Vessel stiffness: Reduced compliance
- Impaired clearance: Aβ drainage受阻
- Hemodynamic changes: Reduced cerebral blood flow
¶ Neuroinflammation and Oxidative Stress
Inflammation and oxidative stress form a vicious cycle in AD .
Inflammatory cells generate reactive oxygen species:
- NADPH oxidase: Major ROS source in microglia
- Mitochondrial ROS: Electron leak during inflammation
- Nitric oxide synthase: Produces NO and peroxynitrite
- Xanthine oxidase: Uric acid metabolism ROS
ROS causes macromolecule damage:
- Lipid peroxidation: Membrane damage, lipid rafts altered
- Protein oxidation: Carbonyl groups, misfolding
- DNA damage: 8-OHdG formation, repair overload
- RNA oxidation: mRNA dysfunction
Endogenous antioxidants are overwhelmed:
- Glutathione: Depleted in AD brain
- SOD/Catalase: Impaired function
- Nrf2 pathway: Dysregulated antioxidant response
- Mitochondrial antioxidants: Reduced efficacy
The NLRP3 inflammasome is a key driver of neuroinflammation .
- NLRP3: Pattern recognition receptor
- ASC: Adaptor protein
- Caspase-1: Protease that activates cytokines
- Aβ crystals: Direct activation
- ATP: P2X7 receptor activation
- ROS: Mitochondrial DAMPs
- Urinary crystals: Amyloid deposits
- IL-1β maturation: Pro-inflammatory cytokine activation
- IL-18 release: IFN-γ stimulating
- Pyroptosis: Inflammatory cell death
- Amplification loop: Chronic inflammation
Astrocytes play complex roles in neuroinflammation .
Astrocyte reactivity in AD:
- GFAP upregulation: Classic marker
- A1 phenotype: Neurotoxic reactive astrocytes
- A2 phenotype: Potentially protective
- S100B release: Pro-inflammatory effects
Inflammation impairs astrocyte functions:
- Glutamate uptake: Excitotoxicity
- Lactate production: Energy failure
- Potassium buffering: Dysregulation
- Water balance: Edema susceptibility
Astrocytes in the neurovascular unit:
- Regulation of cerebral blood flow: Impaired
- BBB maintenance: Compromised
- Aβ clearance: Reduced
- Angiogenesis: Abnormal responses
Neuroinflammation shows sex-based differences in AD .
Women show:
- Higher microglial activation: Post-mortem studies
- More pronounced inflammation: Biomarker studies
- Hormonal modulation: Estrogen anti-inflammatory effects
- Genetic factors: Sex-specific genetic architecture
Men show:
- Different cytokine profiles: Some studies
- Microglial morphology differences: Age-related
- Autoimmune comorbidity effects: Variable
Inflammatory processes show circadian regulation .
- IL-6 peaks: Nighttime in humans
- TNF-α: Circadian oscillation
- Microglial surveillance: Time-of-day variation
- Aβ production: Diurnal pattern
¶ Sleep and Inflammation
Bidirectional relationship:
- Sleep deprivation: Increases inflammation
- AD pathology: Disrupts sleep
- Microglial activation: Sleep-wake dependent
- Therapeutic implications: Sleep interventions
Inflammation is epigenetically regulated .
- Inflammatory genes: Hypomethylated in AD
- TREM2: Methylation changes
- Genome-wide: Altered patterns
- Histone acetylation: Pro-inflammatory gene activation
- HDAC inhibitors: Potential therapy
- H3K27ac: Enhanced inflammatory response
- miR-155: Pro-inflammatory microRNA
- miR-146a: Anti-inflammatory, dysregulated
- lncRNAs: Inflammatory regulation
¶ Neuroinflammation and Neurogenesis
Chronic inflammation impairs neurogenesis .
- Hippocampal niche: Dentate gyrus
- Impaired in AD: Reduced proliferation
- Inflammatory mediators: Anti-neurogenic
- Therapeutic potential: Inflammation reduction
- Cytokine effects: Directly inhibit neurogenesis
- Microglial phagocytosis: Engulf neural precursors
- Niche inflammation: Disrupted environment
- Vascular changes: Impaired niche function
Metabolic dysfunction and inflammation are linked .
- Brain insulin resistance: Type 3 diabetes concept
- Inflammatory signaling: IRS1 dysfunction
- Aβ-insulin interaction: Competitive clearance
- Therapeutic approaches: Insulin sensitizers
- APOE effects: Lipid transport inflammation
- Fatty acids: Pro/anti-inflammatory
- Lipid rafts: Signaling platform alterations
- Eicosanoids: Prostaglandin leukotriene balance
- Combination therapy: Multiple inflammatory pathways
- Personalized medicine: Patient-specific inflammation profiles
- Timing considerations: Early intervention importance
- Biomarker-driven: Patient selection
- TREM2 modulation: Agonists in development
- CD33 inhibition: Genetic validation
- NLRP3 blockers: Clinical trials ongoing
- Microglial repopulation: CSF1R approaches
Neuroinflammation in AD represents a complex, multi-cellular process that both drives and is driven by other pathological features. Understanding the bidirectional relationships between inflammation, amyloid, tau, and synaptic dysfunction provides crucial insights for developing effective therapeutic interventions. As research advances, targeting specific inflammatory pathways while preserving beneficial immune functions remains a key challenge and opportunity in AD therapy.
¶ Clinical Translation and Therapeutic Implications
The translation of neuroinflammatory mechanisms into clinical therapies has proven challenging, with multiple approaches evaluated in clinical trials .
Targeting pro-inflammatory cytokines represents a direct approach:
- IL-1β inhibition: Anakinra (IL-1 receptor antagonist) has been tested in small AD trials with mixed results. The challenge lies in timing—blocking IL-1β too late may not reverse established pathology.
- TNF-α inhibition: Etanercept (TNF receptor-Fc fusion) showed promise in pilot studies but failed in larger trials. Perispinal delivery remains investigational.
- IL-6 signaling: Tocilizumab (anti-IL-6R) is being evaluated for its potential to modulate neuroinflammation in AD patients.
Modulating microglial function rather than broadly suppressing inflammation shows promise:
- TREM2 agonism: Anti-TREM2 antibodies (e.g., from Genentech, AbbVie) are in early-phase trials aiming to enhance microglial phagocytosis of Aβ plaques. The gantenerumab and remibrutinib programs have shown target engagement in Phase 1/2 studies.
- CSF1R inhibitors: PLX5622 (Plexxikon) depletes microglia in animal models but raises concerns about removing beneficial microglial functions. Clinical trials in AD are ongoing.
- CD33 inhibition: Genetic evidence supports CD33 as an AD risk gene; anti-CD33 antibodies are in preclinical development.
The NLRP3 inflammasome is a key driver of neuroinflammation:
- MCC950: A potent NLRP3 inhibitor showed efficacy in animal models but failed in early clinical trials due to liver toxicity. Next-generation inhibitors are in development.
- Dapansutrile (OLT1177): An oral NLRP3 inhibitor has completed Phase 1/2 trials in cardiovascular disease and is being evaluated for neurodegenerative applications.
- Natural compounds:Quercetin and other flavonoids show NLRP3-modulating activity in preclinical models.
Translational biomarkers enable patient selection and monitor therapeutic response .
- IL-1β: Elevated in AD vs. controls; correlation with cognitive decline
- IL-6: Predicts progression from MCI to AD
- YKL-40: Microglial activation marker; tracks with disease severity
- sTREM2: Soluble TREM2 reflects microglial activity; bidirectional relationship with disease stage
- Neurofilament light chain (NfL): Axonal damage marker; responds to anti-inflammatory treatment
- IL-6, TNF-α: Elevated in AD; potential for screening
- GFAP: Astrocyte activation; emerging blood marker
- p-tau/total tau ratio: Differentiates AD from other dementias
- TSPO PET: Measures microglial activation in vivo. First-generation ligands (11C-PK11195) showed increased binding in AD. Second-generation tracers (18F-GE-180, 18F-DPA-714) offer improved kinetics.
- FDG-PET: Metabolic imaging complements inflammatory markers
Major clinical trials targeting neuroinflammation in AD:
| Trial/Agent |
Target |
Phase |
Status |
| Verubecestat (MK-8931) |
BACE1 inhibitor |
Phase 3 |
Terminated (cognitive worsening) |
| Tilisolizumab (NI-0401) |
CD40/CD40L |
Phase 2 |
Completed |
| Sargramostim (GM-CSF) |
Immunomodulation |
Phase 2 |
Completed |
| Azeliragon (TTP-488) |
RAGE inhibitor |
Phase 3 |
Failed |
| Lorecivivint (SM04790) |
Wnt signaling |
Phase 2 |
Ongoing |
| AL002 (Alector) |
TREM2 agonist |
Phase 2 |
Ongoing |
A critical challenge is identifying the optimal intervention window:
- Preclinical stage: Anti-inflammatory approaches may prevent disease onset in at-risk individuals
- MCI stage: May represent the optimal window for disease-modifying therapies
- Moderate dementia: Aggressive anti-inflammatory approaches may be too late
Given the multifactorial nature of AD, combination therapies are logical:
- Anti-amyloid + anti-inflammatory: Lecanemab + NLRP3 inhibitor
- Anti-tau + immunomodulation: Anti-tau antibodies + TREM2 modulators
- Metabolic + anti-inflammatory: Intranasal insulin + anti-cytokine therapy
Patient selection based on inflammatory biomarkers:
- TREM2 variant carriers: May benefit from TREM2 agonism
- High inflammatory profile: Prioritize anti-inflammatory approaches
- APOE4 carriers: May have increased inflammatory response
¶ Patient Impact and Clinical Relevance
Neuroinflammation directly impacts patient outcomes:
- Cognitive function: Inflammatory cytokines impair synaptic plasticity and memory
- Behavioral symptoms: Neuroinflammation contributes to agitation, depression, and psychosis
- Functional decline: Inflammation correlates with activities of daily living (ADL) deterioration
Managing neuroinflammation-related symptoms:
- Agitation management: Anti-inflammatory approaches may reduce neuropsychiatric symptoms
- Sleep disturbances: Inflammation disrupts circadian rhythms; treating inflammation may improve sleep
- Daily functioning: Reducing inflammation may preserve functional abilities longer
¶ Challenges and Future Directions
- Early intervention- Biomarker-driven trials: Enriching trials with patients sho- Combination therapies: Simultaneous